ERBB2 and breast cancer: Despite the fact that HER2-directed therapeutic approaches have improved outcomes in early stage HER2pos BC, many patients remain at risk of relapse or death.10 11 Polychemotherapy regimen is a standard neoadjuvant treatment added to HER2-targeted antibodies for patients with HER2pos BC, but some patients suffer from significant toxicity.